EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Helicobacter pylori infection using a novel antiadhesion compound (3'sialyllactose sodium salt). A double blind, placebo-controlled clinical study



Treatment of Helicobacter pylori infection using a novel antiadhesion compound (3'sialyllactose sodium salt). A double blind, placebo-controlled clinical study



Helicobacter 8(4): 252-256



Background and Aim: 3' sialyllactose sodium salt (3'SL) is an oligosaccharide that occurs naturally in human and bovine milk. It can inhibit the adhesion of H. pylori to human epithelial cells in vitro. The aim of this study was to test whether this oligosaccharide can suppress or cure H. pylori colonization in vivo and to determine its safety in humans. Methods: Seventy-one consecutive dyspeptic patients with H. pylori infection documented by histology and 13C-Urea Breath Test (UBT) were initially recruited to this study. Patients with UBT values <15 were excluded, thus reducing the enrolment to 65 patients. They were given two different dosages of 3'SL (10 g or 20 g/day) in three daily administrations before meals or placebo for 4 weeks, according to a randomised double-blind protocol. A standardized 13C-UBT (using 100 mg of 13C labelled urea) was repeated in all patients at fixed intervals during treatment (at the end of weeks 1, 2 and 4) and 4 weeks after treatment withdrawal. Patients compliance and side-effects were evaluated at each weekly visit. Results: Five patients were excluded from the PP analysis due to violation of the protocol (noncompliance, lost to follow-up), whereas 61 patients completed correctly the study: 17 received 3'SL 10 g/day, 22 were treated with 3'SL 20 g/day and 21 were given placebo. The three treatment groups did not significantly differ in demographic or clinical patient characteristics. No serious adverse events were observed during therapy in any of the three groups. No patients became UBT negative (<4) during or after treatment but UBT values decreased significantly during the study period in both treatment groups and placebo. Conclusions: Antiadhesive therapy was safe and well tolerated but did not suppress or cure H. pylori colonization in humans. The observed decrease in UBT values could be explained by a regression towards the mean effect.

(PDF emailed within 0-6 h: $19.90)

Accession: 011590916

Download citation: RISBibTeXText

PMID: 12950597

DOI: 10.1046/j.1523-5378.2003.00152.x



Related references

Treatment of H pylori infection using a novel anti-adhesion compound A double-blind, randomised, placebo-controlled clinical study. American Journal of Gastroenterology 95(9): 2451-2452, September, 2000

Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 81(4): 387-393, 2007

Garlic in the treatment of Helicobacter pylori infection, a double blind randomized placebo controlled trial. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1289, April, 2000

Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection a prospective, randomized, double blind, and placebo-controlled study. Phytomedicine: 6 7, 391-399, 2008

Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: a prospective, randomized, double blind, and placebo-controlled study. Phytomedicine 15(6-7): 391-399, 2008

Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. Phytomedicine 15(6-7): 391-399, 2008

Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. Digestive Diseases and Sciences 51(1): 89-98, 2006

Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. Journal of Clinical Gastroenterology 48(5): 407-413, 2014

Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. Allergologia et Immunopathologia 30(5): 255-258, 2002

Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therapeutic Advances in Gastroenterology 7(1): 4-13, 2014

The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter 18(4): 280-284, 2013

Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics 14(3): 317-324, 2000

Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 15(10): 1603-1611, October, 2001

Treatment of non-ulcer dyspepsia associated with Helicobacter pylori with omeprazole + clarithromycin A placebo-controlled, double blind study. Gastroenterology 112(4 SUPPL ): A221, 1997

The recurrence of duodenal ulcer after treatment for Helicobacter pylori. A randomized, double-blind, placebo-controlled study. G.E.N 46(4): 302-306, 1992